sign free newsletters sign free newsletters decision contradicts earlier halt studies therapy followed series failed drugs targeted diseased brain protein shocking reversal biogen tuesday said resurrect alzheimer drug company ask food drug administration approve company said new analysis larger dataset showed drug aducanumab reduced clinical decline patients early alzheimer disease multiple measures drug effectiveness directly contradicts decision march halt studies therapy based recommendations independent monitoring board charged protecting patients study aducanumab failure sent shock waves far biogen thought series drugs previous ones different drug companies failed targeted protein brain called beta amyloid biogen announcement march researchers biotechnology executives saw little